EP1289528A1 - Combinaison de principes actifs contenant un opioide a structure du type fentanyle et de la cetamine - Google Patents

Combinaison de principes actifs contenant un opioide a structure du type fentanyle et de la cetamine

Info

Publication number
EP1289528A1
EP1289528A1 EP01940449A EP01940449A EP1289528A1 EP 1289528 A1 EP1289528 A1 EP 1289528A1 EP 01940449 A EP01940449 A EP 01940449A EP 01940449 A EP01940449 A EP 01940449A EP 1289528 A1 EP1289528 A1 EP 1289528A1
Authority
EP
European Patent Office
Prior art keywords
active ingredient
radical
pharmaceutical formulation
formulation according
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01940449A
Other languages
German (de)
English (en)
Inventor
Boris Chizh
Thomas Christoph
Werner Englberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of EP1289528A1 publication Critical patent/EP1289528A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Definitions

  • the present invention relates to an active ingredient combination
  • an active ingredient combination comprising as active ingredient component a) at least one opioid compound with a fentanyl-like structure and / or its enantiomer and / or its diastereomer and / or at least one corresponding pharmaceutically acceptable salt and as active ingredient component b) ketamine and / or at least one of its physiologically tolerated salts, the weight ratio of active ingredient component a) to active ingredient component b) being in the range from 1:20 to 1: 1500, pharmaceutical formulations and pharmaceutical compositions containing this active ingredient combination and the use of this active ingredient combination for the preparation of drugs.
  • Neuropathic pain is a special form of chronic pain, which is caused by various injuries to the peripheral or central nervous system and which cannot be adequately treated with conventional pain relievers, such as opioids.
  • opioids Another disadvantage of opioids is that they often have a very short duration of action and very often cause undesirable side effects such as respiratory depression, nausea, vomiting, dependency, sedation, constipation or development of tolerance.
  • One class of analgesic compounds that are useful in combating neuropathic pain are the N-methyl-D-aspartate (NMDA) antagonists.
  • NMDA N-methyl-D-aspartate
  • these often have a very short duration of action and often have very pronounced undesirable side effects, such as hallocinogenic effects, coordination disorders, sedation, nausea or itching.
  • U.S. Patent 5,321,012 discloses pharmaceutical compositions of an anesthetic analgesic and another active ingredient, such as e.g. an NMDA antagonist.
  • an NMDA antagonist e.g. an NMDA antagonist.
  • the joint application of the narcotic pain reliever with such active substances is intended to prevent the development of tolerance or the development of a dependency on the narcotic pain reliever.
  • an active substance combination comprising as active substance component a) at least one opioid compound with a fentanyl-like structure and / or one of its enantiomers and / or one of its diastereomers and / or at least one corresponding physiologically tolerated salt and as active substance component b) ketamine and / or at least one of its physiologically tolerable salts in certain weight ratios has a long-lasting analgesic effect and is therefore suitable for combating of pain, particularly suitable for combating neuropathic pain.
  • the present invention therefore relates to an active ingredient combination which
  • the combination of active substances according to the invention surprisingly shows a long-lasting analgesic effect which extends far beyond the duration of action of either of the two active substances alone and is thus outstandingly suitable for combating pain, in particular for combating neuropathic and / or acute pain, with the undesirable side effects which are usually associated with the application of opioids or NMDA antagonists does not occur or only occurs for a significantly shorter period of time and only occurs in a significantly weakened form than when the individual active ingredient components are applied.
  • the active ingredient combination according to the invention can contain the opioid compounds with a fentanyl-like structure, their diastereomers, their enantiomers and their corresponding physiologically tolerable salts, either individually or in mixtures of at least two of these compounds.
  • the active ingredient combination according to the invention preferably contains an opioid compound with a fentanyl-like structure, its enantiomer, diastereomer or a corresponding physiologically tolerated salt.
  • the active compound combination according to the invention contains as component a) at least one compound of the general formula I,
  • the radical R 2 represents a phenyl radical or a phenyl radical which is optionally substituted in the ortho position by fluorine or a 2-pyrazinyl radical,
  • R 3 for H, a C ⁇ . 3 -alkoxymethyl, a -C-3-alkoxycarbonyl or a phenyl radical
  • the radicals R 4 and R 5 identical or different, each represent H, OH or a C 1-3 alkyl radical
  • radicals R 6 and R 7 each represent H or a C 1-3 alkyl radical
  • Radical R 9 represents a phenyl, a 2-thienyl, a C ⁇ -3 -alkoxycarbonyl or a 1-ethyl-1, 4-dihydro-tetrazol-5-one radical,
  • the active substance combination according to the invention as component a) fentanyl, alfentanil, Brifentanil, carfentanil, Fenaridin, Fentatienil, lofentanil, Ocfentanil, Mefentanil, Mirfentanil, remifentanil, sufentanil, Trefentanil and / or one of its enantiomers and / or one of its diastereoisomers and / or at least one corresponding physiologically compatible salt or a mixture of at least two of the above-mentioned compounds.
  • hydrochloride, hydrobromide, sulfate, sulfonate, phosphate, tartrate, embonate, formate, acetate, propionate, benzoate, oxalate, succinate can preferably be used as the physiologically compatible salt of the opioid compound with a fentanyl-like structure and / or its enantiomer and / or its diastereomer , Citrate, glutamate, fumarate, aspartate, glutarate, stearate, butyrate, malonate, lactate, mesylate or a mixture of at least two of these salts.
  • the hydrochloride, hydrobromide, sulfate, sulfonate, phosphate, tartrate, embonate, formate, acetate, propionate, benzoate, oxalate, succinate, citrate, glutamate, fumarate, aspartate, glutarate, stearate, butyrate, malonate can preferably be used as the physiologically compatible salt of ketamine , Lactate, mesylate or a mixture of at least two of these salts.
  • the weight ratio of active ingredient component a) to active ingredient component b) is in the range from 1:50 to 1: 1000, particularly preferably in the range from 1: 100 to 1: 550.
  • Another object of the invention is also pharmaceuticals containing the active ingredient combination according to the invention and optionally further active ingredients and / or excipients.
  • the medicaments according to the invention are preferably used to combat pain, in particular to combat neuropathic and / or acute pain.
  • the present invention further also relates to pharmaceutical formulations in different administration forms which contain the active compound combination according to the invention and, if appropriate, further active compounds and / or auxiliaries.
  • the pharmaceutical formulations are in the form of tablets, chewable tablets, chewing gums, dragees, capsules, drops, juices, syrups, suppositories, transmucal therapeutic systems, transdermal therapeutic systems, solutions, emulsions, suspensions, easily reconstitutable dry preparations, powders or sprays ,
  • Particularly preferred pharmaceutical formulations are tablets, capsules, drops, solutions, transmucal therapeutic systems or transdermal therapeutic systems.
  • the pharmaceutical formulations according to the invention are in multiparticulate form, preferably as microtablets, microcapsules, microspheroids, micropellets, ion exchange resinates, granules, active ingredient crystals or pellets, particularly preferably as microtablets, granules or pellets.
  • Pellets in the sense of the present invention also include pellets produced by extrusion and / or spheronization.
  • compositions according to the invention are preferably suitable for oral, intravenous, intramuscular, subcutaneous, intrathecal, epidural, buccal, sublingual, pulmonary, rectal, transdermal, transmucal, nasal or intracerebroventricular application, pharmaceutical formulations for oral, transdermal or intravenous, transmucal, application being particularly preferred ,
  • Preparations in the form of tablets, chewable tablets, chewing gums, dragees, capsules, granules, drops, juices and syrups are preferably suitable for oral administration.
  • a transmucal therapeutic system is preferably suitable for buccal application.
  • Solutions, suspensions, emulsions, easily reconstitutable dry preparations, microspheroids, sprays, suppositories or plasters are preferably suitable for parenteral, topical and inhalation application. Suppositories or solutions are particularly preferably used for parenteral administration, transdermal therapeutic systems for topical administration and powders or solutions for inhalation administration.
  • compositions according to the invention In addition to an active ingredient combination according to the invention, further carrier materials, fillers, solvents, diluents, dyes, flavorings, binders or mixtures of at least two of these materials can be used to prepare the pharmaceutical formulations according to the invention.
  • the choice of excipients and their amount depends on the manner in which the medicinal product is to be applied. The person skilled in the art is aware of the auxiliaries suitable for the particular form of application and their amounts.
  • the pharmaceutical formulations according to the invention can be prepared by the customary methods known to the person skilled in the art.
  • the pharmaceutical formulations according to the invention can also contain at least one of the active ingredient components a) or b) in a delayed form.
  • the respective active ingredient component is preferably retarded by a retarding coating, by fixation to an ion exchange resin, by embedding in a retarding matrix or by a combination of these different retardations.
  • Suitable retarding coatings include water-insoluble waxes or polymers such as e.g. Acrylic resins, preferably poly (meth) acrylates, or water-insoluble celluloses, preferably ethyl cellulose. These materials are from the prior art, e.g. Bauer, Lehmann, Osterwald, Rothgang “Coated Pharmaceutical Forms", Erasmusliche Verlagsgesellschaft mbH Stuttgart, 1988, page 69 ff., Are hereby introduced as a reference and are therefore considered part of the disclosure.
  • the retarding coatings can optionally also be non-retarding, preferably water-soluble polymers in amounts of up to 30 wt , Sodium chloride or mannitol and / or the known plasticizers.
  • the pharmaceutical formulation according to the invention can have further coatings. Coatings that dissolve depending on the pH can also be present as coatings. It can thus be achieved that the pharmaceutical formulation passes through the gastrointestinal tract undissolved and the active substance combination according to the invention is only released in the intestinal tract. Coatings can also be used to improve the taste.
  • ion exchange resins Another common method of retardation is the fixation of the active ingredients to ion exchange resins.
  • cationic ion exchange resins preferably polystyrene sulfonates
  • the active ingredient combination according to the invention can also be present in a retarding matrix, preferably evenly distributed.
  • Physiologically compatible, hydrophilic materials which are known to the person skilled in the art can be used as matrix materials.
  • Polymers, particularly preferably cellulose ethers, cellulose esters and / or acrylic resins, are preferably used as the hydrophilic matrix materials.
  • the matrix materials used are very particularly preferably ethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxymethyl cellulose, poly (meth) acrylic acid and / or their derivatives, such as their salts, amides or esters.
  • Matrix materials made from hydrophobic materials such as hydrophobic polymers, waxes, fats, long-chain fatty acids, fatty alcohols or corresponding esters or ethers or mixtures thereof, are also preferred.
  • the hydrophobic materials mono- or diglycerides of C 2 -C3o fatty acids and / or C ⁇ 2 -C 3 Particularly preferred are o-fatty alcohols and / or waxes or mixtures thereof.
  • the pharmaceutical formulation according to the invention contains at least one of the active ingredient components a) or b) in addition to its retarded form and also in its unretarded form. Combined with the immediately released active ingredient, a high initial dose can be achieved for quick pain relief. The slow release from the retarded form then prevents the analgesic effect from subsiding.
  • the amount of the active ingredient combination according to the invention to be administered to the patient is known to the person skilled in the art from the use of the individual components and varies, for example, depending on the weight of the patient, the type of application, the indication and the severity of the disease.
  • the amount to be administered and the release of the active compound combination according to the invention are preferably adjusted so that they have to be applied at most twice, preferably only once a day.
  • Another object of the present invention is the use of a combination of active substances according to the invention and optionally further active substances and / or auxiliaries for the production of a medicament.
  • the active ingredient combination according to the invention is preferably used for the production of a medicament for combating pain, in particular for combating neuropathic and / or acute pain.
  • the active ingredient combination according to the invention surprisingly exhibits a long-lasting analgesic effect which reaches its maximum about 15 minutes after its application and which, even after 24 hours, is greatly improved compared to the application of each of the two active ingredient components a) and b) alone and is much longer lasting.
  • This long-lasting analgesic effect has the advantage that the dose of active ingredient components a) and b) required for effective pain control can be reduced per day.
  • the rats were first anesthetized with pentobarbital (50 mg per kg body weight of the rat Nembutal ® , ip, Sanofi, rudenschaft yerr Tierä für eG, Hanover, Germany). Multiple unilateral ligatures were then performed on the right main sciatic nerve of the rats. For this purpose, the sciatic nerve was exposed at the middle of the thigh and four loose ligatures (softcat ® chrom USP 4/0, metric2, Braun Mels Institute, Germany) were bound around the sciatic nerve so that the epineural blood flow was not interrupted. After this operation, the rats were able to recover for a week. The rats developed an allodynia against cold that lasted for at least five weeks.
  • This allodynia was tested on a metal plate that was heated to a temperature of 4 ° C with the help of a water bath.
  • the rats were divided into groups of 7 or 8 animals before the intravenous application of the respective solution.
  • the rats were placed on the cold metal plate, which was in a plastic cage. Then, over a period of two minutes before the application of a solution, the number of times the animals jerked violently back with their damaged paw from the cooled metal plate was counted. The corresponding number of these reactions of the rats is denoted by (W).
  • the corresponding solutions were then administered intravenously and the pain measurement was carried out after 15, 30, 45, 60, 120, 180 and 1440 minutes. The corresponding number of these reactions of the rats is denoted by (WN).
  • the analgesic effect was seen as a decrease in the frequency of W
  • the rats flinching (% of the maximum possible antinociceptive effect) determined according to the following formula:
  • a 0.9% saline solution containing only 4.64 mg ketamine per kg body weight of the rat was administered intravenously to a second group of 7 rats.
  • a third group of 7 rats was given a 0.9% saline solution containing only 0.01 mg fentanyl per kg body weight of the rat intravenously.
  • FIG. 1 shows that the comparative solution according to comparative example 1, which contains only the ketamine, has a good analgesic effect about 15 minutes after its application, which lasts for a period of about 3 hours and then wears off.
  • the comparative solution according to comparative example 2 which contains only the fentanyl, has a good analgesic effect over a period of 15 minutes after application, but this then wears off very quickly. An hour after application, fentanyl alone shows almost no analgesic effect.
  • the application of the solution of the active substance combination of ketamine and fentanyl has an analgesic effect which reaches its maximum approximately 15 minutes after the application and its analgesic effect over a period of approximately 45 minutes after the application compared to the sole application of ketamine or fentanyl is significantly improved. Also 1440 minutes, i.e. 24 hours after their application, the solution of the active compound combination according to the invention continues to have a clearly pronounced analgesic effect, while the comparative solutions according to Comparative Examples 1 and 2 no longer have any analgesic effect after this period.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une combinaison de principes actifs contenant, comme composant a), au moins un composé opioïde présentant une structure du type fentanyle et/ou ses énantiomères et/ou ses diastéréomères et/ou au moins un sel pharmaceutiquement acceptable correspondant, et, comme composant b), de la cétamine et/ou au moins un de ses sels physiologiquement compatibles, le rapport pondéral du composant a) au composant b) étant compris dans la plage 1:20-1:1500. L'invention concerne également des formulations de médicaments et des médicaments contenant cette combinaison de principes actifs, ainsi que l'utilisation de celle-ci pour la production de médicaments.
EP01940449A 2000-05-26 2001-05-10 Combinaison de principes actifs contenant un opioide a structure du type fentanyle et de la cetamine Withdrawn EP1289528A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10025946 2000-05-26
DE10025946A DE10025946A1 (de) 2000-05-26 2000-05-26 Wirkstoffkombination
PCT/EP2001/005348 WO2001091753A1 (fr) 2000-05-26 2001-05-10 Combinaison de principes actifs contenant un opioide a structure du type fentanyle et de la cetamine

Publications (1)

Publication Number Publication Date
EP1289528A1 true EP1289528A1 (fr) 2003-03-12

Family

ID=7643550

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01940449A Withdrawn EP1289528A1 (fr) 2000-05-26 2001-05-10 Combinaison de principes actifs contenant un opioide a structure du type fentanyle et de la cetamine

Country Status (10)

Country Link
US (1) US20040092531A1 (fr)
EP (1) EP1289528A1 (fr)
JP (1) JP2003534378A (fr)
AU (1) AU2001274021A1 (fr)
CA (1) CA2406976A1 (fr)
DE (1) DE10025946A1 (fr)
HU (1) HUP0301972A3 (fr)
MX (1) MXPA02011610A (fr)
NZ (1) NZ521878A (fr)
WO (1) WO2001091753A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US8084058B2 (en) * 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004026241A2 (fr) * 2002-09-20 2004-04-01 Andrx Labs Llc Nouvelle preparation pharmaceutique contenant un biguanide et un derive de la thiazolidinedione
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2005058319A1 (fr) * 2003-12-16 2005-06-30 Cnsbio Pty Ltd Methodes et compositions
US20060052370A1 (en) * 2004-08-24 2006-03-09 Meyerson Laurence R Methods and compositions for treating nociceptive pain
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
CN101378732A (zh) * 2006-01-06 2009-03-04 阿塞尔Rx制药有限公司 用于口腔经粘膜递送的生物粘附药物制剂
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
WO2009131794A1 (fr) * 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Combinaisons de co-médicament opioïdekétamine et norkétamine dans la gestion de la douleur
KR101660996B1 (ko) * 2008-09-16 2016-09-28 넥타르 테라퓨틱스 남용에 대한 낮은 잠재성을 갖는 페길화 오피오이드
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
WO2011123866A1 (fr) * 2010-04-02 2011-10-06 Alltranz Inc. Formulations transdermiques empêchant les abus constituées d'agonistes et d'agonistes/antagonistes d'opiacés
JP6506248B2 (ja) 2013-03-14 2019-04-24 ゾーン・ロイヤリティズ・アンド・マイルストーンズ・エルエルシー 二環式鎮痛化合物
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
CN108947867A (zh) 2013-12-12 2018-12-07 卡利拉制药公司 双环烷基化合物及合成
CA2942144C (fr) 2014-03-07 2023-08-22 Kalyra Pharmaceuticals, Inc. Derives de propellane et synthese
CN106999451B (zh) 2014-09-17 2021-04-02 里科瑞尔姆Ip控股有限责任公司 双环化合物
AU2015369710B2 (en) 2014-12-23 2020-09-17 Vertical Pharmaceuticals, Llc Systems, devices and methods for dispensing oral transmucosal dosage forms
WO2017160926A1 (fr) * 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Composés analgésiques
US9650338B1 (en) * 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
JP7157769B2 (ja) 2017-05-15 2022-10-20 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 鎮痛剤化合物
EP3965733A4 (fr) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. Formes posologiques dissuasives d'abus contenant de l'eskétamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11160799B2 (en) * 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254124A (en) * 1962-06-29 1966-05-31 Parke Davis & Co Aminoketones and methods for their production
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
CA2230690C (fr) * 1995-08-30 2008-12-23 Stuart L. Weg Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments
PT1102589E (pt) * 1998-07-16 2006-12-29 Memorial Sloan Kettering Inst Composições tópicas compreendendo um analgésico opióide e um antagonista do nmda

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO0191753A1 *

Also Published As

Publication number Publication date
AU2001274021A1 (en) 2001-12-11
HUP0301972A3 (en) 2005-06-28
DE10025946A1 (de) 2001-11-29
CA2406976A1 (fr) 2002-10-22
MXPA02011610A (es) 2003-05-14
NZ521878A (en) 2005-08-26
HUP0301972A2 (hu) 2003-11-28
WO2001091753A1 (fr) 2001-12-06
US20040092531A1 (en) 2004-05-13
JP2003534378A (ja) 2003-11-18

Similar Documents

Publication Publication Date Title
EP1289528A1 (fr) Combinaison de principes actifs contenant un opioide a structure du type fentanyle et de la cetamine
EP1183015B1 (fr) Comprime a couches multiples pour l'administration d'une combinaison fixe de tramadol et de diclofenac
DE69233699T2 (de) Oxycodonzusammensetzungen mit kontrollierter Freisetzung
EP1020185B1 (fr) Opioides analgésiques à libération contrôlée
EP1143936A2 (fr) FORMULATIONS DE MEDICAMENTS CONTENANT UN OPIOIDE ET UN $g(a)-AGONISTE
WO2001015682A1 (fr) Sels pharmaceutiques de tramadol
EP0857065A2 (fr) Utilisation de 4-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene pour la prophylaxie et le traitement des sequelles d'une insuffisance de vascularisation cerebrale aigüe et chronique et de maladies neurodegeneratives
EP1185253B1 (fr) Forme galenique orale servant a administrer une combinaison fixe de tramadol et de diclofenac
WO2002066026A2 (fr) Medicament a base de tramadol
AT4589U2 (de) Oxycodon-zusammensetzung mit kontrollierter freisetzung
EP1020183A2 (fr) Composition analgésique à libération contrôlée
EP1289529B1 (fr) Combinaison de substances comprenant un compose a effet opioide et un autre compose de la formule i
WO2012016646A1 (fr) Comprimés de quétiapine
DE602004008440T2 (de) Pharmazeutische kombinationspräparat zur behandlung von spastischkeit und/oder schmerzen
WO2001091732A2 (fr) Medicament pour lutter contre la depression respiratoire
DE19743323C2 (de) Feste Arzneimittelzusammensetzung auf der Grundlage von Selegilin
WO2002066025A2 (fr) Combinaison de principes actifs
WO2001091733A2 (fr) Combinaison de principes actifs contenant de la montireline et un compose a effet opioide
DE3829398C2 (fr)
EP1382338B1 (fr) Comprimé à libération controlée comprenant du tilidine et un photoprotecteur
WO2018087109A1 (fr) Forme galénique multiparticulaire à libération de métamizole contrôlée
DE10250566A1 (de) Pharmazeutische Zusammensetzung, enthaltend Oxcarbazepin mit verzögerter Wirkstofffreisetzung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ENGLBERGER, WERNER

Inventor name: CHRISTOPH, THOMAS

Inventor name: CHIZH, BORIS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/04 20060101ALI20070227BHEP

Ipc: A61K 31/135 20060101ALI20070227BHEP

Ipc: A61K 31/4468 20060101AFI20070227BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070724